SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Committee Report to the
SNMMI Board of Directors
June 2015

Joint Compounding Task Force

Committee Charges:

- Monitor and comment on federal and state compounding legislation in coordination with the Committee on Radiopharmaceuticals.
- Develop SNMMI/TS official statements re: compounding policies for approval by the SNMMI Board of Directors.
- Create educational programs for compounding professionals who prepare radiopharmaceuticals (both for immediate use and bulk batch preparations).
- Develop white paper describing the standing of properly trained and credentialed nuclear medicine technologists as compounding professionals.

Current Working Objectives/Goals (please reference Strategic Plan):

- Review of FDA regulations

Progress of Charge/Objectives/Goals to Date:

1. Review of FDA regulations

The Task Force continues to focus the majority of its work on developing recommendations to the FDA on compounding. The Task Force submitted follow-up to FDA in March regarding the distinction of nuclear pharmacy from manufacturing and from a PET drug production facility. SNMMI was invited back to FDA for a second meeting on compounding in April. The Task Force provided representation and discussed recommended descriptions of compounding and preparation as well specifics of minor deviation, interstate delivery percentages, and state regulations related to patient name on prescriptions.

The Task Force is currently preparing a follow up letter for the April meeting to further clarify and reiterate SNMMI's recommendations on minor deviation, patient name, and interstate delivery.